Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study for Safety and Efficacy Evaluation of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (R/R Ph + ALL)

Next Previous
Search
Trial Profile

Study for Safety and Efficacy Evaluation of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (R/R Ph + ALL)

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 31 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dexamethasone (Primary) ; Lisaftoclax (Primary) ; Olverembatinib (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use

    • Most Recent Events

    • 10 Dec 2024 Results (n=10) presented at the 66th American Society of Hematology Annual Meeting and Exposition.
    • 10 Dec 2024 According to an Ascentage Pharma media release, data from this study presented at the 66th American Society of Hematology (ASH) Annual Meeting, taking place in San Diego, CA, the United States.
    • 06 Nov 2024 According to an Ascentage Pharma media release, data from this trial to be presented, at the 66th American Society of Hematology (ASH) Annual Meeting. The 66th ASH Annual Meeting will take place on Dec 7-10, 2024, local time, both online and in-person in San Diego, CA (United States).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top